(Q50920911)

English

Interleukin-21 (IL-21) synergizes with IL-2 to enhance T-cell receptor-induced human T-cell proliferation and counteracts IL-2/transforming growth factor-β-induced regulatory T-cell development.

scientific article published in May 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23278180

Interleukin-21 (IL-21) synergizes with IL-2 to enhance T-cell receptor-induced human T-cell proliferation and counteracts IL-2/transforming growth factor-β-induced regulatory T-cell development. (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23278180

Alessandra Battaglia

1

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23278180

Margherita Fanelli

4

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23278180

5

object named as

Marco Fossati

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23278180

Giovanni Scambia

7

object named as

Giovanni Scambia

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23278180

Alexia Buzzonetti

2

object named as

Alexia Buzzonetti

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23278180

Valentina Catzola

6

object named as

Valentina Catzola

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23278180

Andrea Fattorossi

8

object named as

Andrea Fattorossi

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23278180

author name string

Cinzia Baranello

3

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23278180

publication date

1 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23278180

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23278180

139

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23278180

1

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23278180

109-120

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23278180

Interleukin-2: clinical applications

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

Tolerance, not immunity, crucially depends on IL-2.

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

Ovarian cancer creates a suppressive microenvironment to escape immune elimination

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

Transforming growth factor-beta regulation of immune responses

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

Cutting Edge: IL-2 is essential for TGF-beta-mediated induction of Foxp3+ T regulatory cells

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

IL-21: roles in immunopathology and cancer therapy

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

Interleukin 21: a cytokine/cytokine receptor system that has come of age

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

A function for IL-7R for CD4+CD25+Foxp3+ T regulatory cells

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

IL-15 acts as a potent inducer of CD4(+)CD25(hi) cells expressing FOXP3.

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

IL-21 promotes survival and maintains a naive phenotype in human CD4+ T lymphocytes.

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

The molecular basis of IL-21-mediated proliferation

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10.

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

FOXP3 and GARP (LRRC32): the master and its minion

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

Nonredundant roles for Stat5a/b in directly regulating Foxp3

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

TGF-beta signalling from cell membrane to nucleus through SMAD proteins

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

How cells read TGF-beta signals

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

Immunotherapy of melanoma by GPI-anchored IL-21 tumour vaccine involves down-regulating regulatory T cells in mouse model

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells.

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

Smad2 and Smad3 are redundantly essential for the TGF-beta-mediated regulation of regulatory T plasticity and Th1 development.

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

IL-27 inhibits the development of regulatory T cells via STAT3

1 reference

https://api.crossref.org/works/10.1111%2FIMM.12061

21 January 2018

Prognostic significance of regulatory T cells in tumor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634543

2 November 2018

Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634543

2 November 2018

IL-21 Counteracts the Regulatory T Cell-Mediated Suppression of Human CD4+ T Lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/23278180

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23278180

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23278180

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/23278180

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IL-21 promotes T lymphocyte survival by activating the phosphatidylinositol-3 kinase signaling cascade

1 reference

https://pubmed.ncbi.nlm.nih.gov/23278180

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/IMM.12061

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23278180

PMC publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23278180

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50920911&oldid=2032981998"